Clarity Pharmaceuticals (ASX:CU6) Cash Flow from Financing : A$0.25 Mil (TTM As of Dec. 2023)

Clarity Pharmaceuticals Cash Flow from Financing Chart

Clarity Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Clarity Pharmaceuticals's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Clarity Pharmaceuticals's Cash from Financing for the quarter that ended in Dec. 2023 is:

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals  (ASX:CU6) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Clarity Pharmaceuticals's issuance of stock for the six months ended in Dec. 2023 was A$0.12 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Clarity Pharmaceuticals's repurchase of stock for the six months ended in Dec. 2023 was A$-0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Clarity Pharmaceuticals's net issuance of debt for the six months ended in Dec. 2023 was A$0.00 Mil. Clarity Pharmaceuticals received A$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Clarity Pharmaceuticals's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. Clarity Pharmaceuticals paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Clarity Pharmaceuticals's cash flow for dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Clarity Pharmaceuticals received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Clarity Pharmaceuticals's other financing for the six months ended in Dec. 2023 was A$0.00 Mil. Clarity Pharmaceuticals received A$0.00 Mil on other financial activities.

Clarity Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description